Trials / Recruiting
RecruitingNCT06077903
GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
A Single Center, Single Arm Phase I Clinical Study of GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
- Status
- Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Grit Biotechnology · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is a single center, single arm phase I clinical trial. This study proposes to enroll 20 subjects, with a trial protocol including chemotherapy pretreatment, reinfusion of autologous tumor infiltrating lymphocyte injection, and interleukin-2 injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GT101 | Autologous tumor infiltrating lymphocyte injection |
Timeline
- Start date
- 2021-07-05
- Primary completion
- 2025-07-01
- Completion
- 2025-07-01
- First posted
- 2023-10-11
- Last updated
- 2025-02-21
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06077903. Inclusion in this directory is not an endorsement.